Spyre Therapeutics develops long-acting antibody therapies and antibody combinations for inflammatory bowel disease and rheumatic diseases. The company’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A and IL-23, with programs such as SPY001, SPY002 and SPY003 evaluated as monotherapies and pairwise combinations.
Recurring news for Spyre Therapeutics includes clinical updates from the SKYLINE platform trial in ulcerative colitis and the SKYWAY basket trial in rheumatic diseases, financial results and corporate updates, common-stock financing activity, and equity inducement awards under its 2018 Equity Inducement Plan. Company announcements also describe balance-sheet actions, development priorities and data presentations tied to its immune-mediated disease pipeline.
Spyre Therapeutics (NASDAQ: SYRE) granted equity inducement awards to four non-executive employees under its 2018 Equity Inducement Plan. The independent Compensation Committee approved stock options for an aggregate 19,436 shares and 6,186 RSUs on August 3, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $94.93, equal to Spyre’s August 3, 2026 closing share price. Options vest 25% on the first employment anniversary and monthly thereafter over four years, while RSUs vest in four equal annual installments on specified quarterly dates, in each case subject to continued service.
Spyre Therapeutics (NASDAQ: SYRE) reported second quarter 2026 results and clinical progress, highlighted by positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE ulcerative colitis trial, which achieved primary histologic endpoints with statistically significant Robart’s Histopathology Index reductions and clinically meaningful remission and endoscopic improvement rates.
The company completed enrollment in all three sub-studies of the Phase 2 SKYWAY basket trial of anti-TL1A antibody SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with proof-of-concept data expected from September through fourth quarter 2026. Spyre reported $1.1453 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, supported by $435.2 million in net proceeds from an April equity offering, and projects cash runway into the second half of 2029. R&D expenses rose to $65.5 million, G&A to $16.1 million, and net loss was $36.2 million for the quarter.
Spyre Therapeutics (NASDAQ: SYRE) granted equity inducement awards to six non-executive employees under its 2018 Equity Inducement Plan.
The awards include stock options for 58,843 shares at an exercise price of $88.89 with a 10-year term, plus 2,134 RSUs, all subject to multi-year vesting and continued service.
Spyre Therapeutics (NASDAQ: SYRE) reported positive 12-week Part A induction data from the Phase 2 SKYLINE trial of SPY002 in moderate-to-severe ulcerative colitis. SPY002 met the primary endpoint with a 10.7-point RHI reduction (p<0.0001), plus 33% clinical remission, 42% endoscopic improvement, and -3.7 modified Mayo Score, with no drug-related serious adverse events.
Spyre Therapeutics (NASDAQ: SYRE) granted stock options to purchase an aggregate of 51,300 shares of common stock to four non-executive employees as equity inducement awards under its 2018 Equity Inducement Plan.
The options have a 10-year term, a $70.54 exercise price, and a time-based vesting schedule tied to continued service.
Spyre Therapeutics (NASDAQ: SYRE) completed enrollment for all sub-studies in the SKYWAY Phase 2 basket trial of SPY072 (anti-TL1A) in rheumatic diseases, including RA, PsA, and axSpA.
The company reiterates Phase 2 efficacy readouts in Q3–Q4 2026 and is presenting supportive preclinical data at EULAR 2026.
Spyre Therapeutics (NASDAQ: SYRE) will participate in two June 2026 healthcare investor conferences. Management joins the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 12:15 pm ET and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, 2026 at 10:00 am ET. Live audio webcasts, replays, and one-on-one investor meetings are planned.
Spyre Therapeutics (NASDAQ:SYRE) reported Q1 2026 results and program updates on May 5, 2026. Key highlights: SPY001 Part A topline induction data showed RHI reduction of 9.2 points (p<0.0001), clinical remission 40%, endoscopic improvement 51%. Company accelerated RA sub-study topline to Q3 2026 and remains on track for six Phase 2 readouts in 2026. Financials: raised $463M gross; pro forma cash of $1.1768B as of March 31, 2026, with expected runway into H2 2029. Q1 net loss was $69.0M.
Spyre Therapeutics (NASDAQ: SYRE) announced inducement stock-option grants to four non-executive employees totaling 20,800 options, approved May 1, 2026 under the 2018 Equity Inducement Plan.
The options carry a 10-year term, an exercise price of $69.42 (Nasdaq close May 1, 2026) and a standard 1/4 then monthly vesting schedule.
Spyre Therapeutics (Nasdaq: SYRE) closed an underwritten public offering on April 16, 2026, selling 7,475,000 shares at $62.00 per share, including full exercise of a 975,000‑share overallotment option. Gross proceeds were approximately $463.5 million before underwriting discounts and offering expenses.
Jefferies, Goldman Sachs, Evercore ISI and Guggenheim acted as joint book‑running managers; a final prospectus supplement was filed April 14, 2026 and related filings became effective February 27, 2026.